2. 筋萎縮性側索硬化症
[臨床試験数:508,薬物数:530(DrugBank:146),標的遺伝子数:170,標的パスウェイ数:221

Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03705390
(ClinicalTrials.gov)
March 29, 201911/9/2018A Safety and Tolerability Study of ILB in Patients With Amyothrophic Lateral Sclerosis (ALS)A Phase II Pilot Single-arm Safety and Tolerability Study of ILB in Patients With Motor Neurone Disease (MND)/ Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosis;Motor Neuron DiseaseDrug: ILBUniversity of BirminghamTikoMed AB;University Hospital Birmingham;NeuregenixRecruiting18 YearsN/AAll15Phase 2United Kingdom
2NCT03613571
(ClinicalTrials.gov)
August 15, 201815/6/2018A Study to Evaluate the Safety, Tolerability and Efficacy of ILB in Patients With Amyotrophic Lateral SclerosisA Single-centre, Open Single-arm Study Where the Safety, Tolerability and Efficacy of Subcutaneously Administered ILB Will be Evaluated in Patients With Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisDrug: ILBTikoMed ABNULLTerminated18 Years80 YearsAll13Phase 2Sweden
3EUCTR2018-000668-28-GB
(EUCTR)
09/08/201825/06/2018A study to assess safety and acceptability of a treatment in patients with ALSA Phase II pilot safety and tolerability study of ILB in patients with Motor Neurone Disease (MND)/Amyotrophic Lateral Sclerosis (ALS) - The ALS Study Motor Neurone Disease (MND)/Amyotrophic Lateral Sclerosis (ALS)
MedDRA version: 20.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
University of BirminghamNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
15Phase 2United Kingdom
4EUCTR2017-005065-47-SE
(EUCTR)
15/05/201819/03/2018A single-center, open single-arm study where the safety, tolerability and efficacy of subcutaneously administered ILB will be evaluated in patients with Amyotrophic Lateral Sclerosis.A single-centre, open single-arm study where the safety, tolerability and efficacy of subcutaneously administered ILB will be evaluated in patients with Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis (ALS);Therapeutic area: Body processes [G] - Immune system processes [G12]TikoMed ABNULLNot Recruiting Female: yes
Male: yes
15Phase 2Sweden